A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
Tara Gurung,1 Deepson S Shyangdan,1 Joseph Paul O’Hare,2 Norman Waugh1 1Warwick Evidence, 2Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK Background: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of...
Main Authors: | Gurung T, Shyangdan DS, O’Hare JP, Waugh N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-08-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Online Access: | http://www.dovepress.com/a-novel-long-acting-glucagon-like-peptide-receptor-agonist-dulaglutide-peer-reviewed-article-DMSO |
Similar Items
-
Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01) -
Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01) -
Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats
by: Vincent N. Marty, et al.
Published: (2020-12-01) -
How glucagon-like peptide 1 receptor agonists work
by: Christine Rode Andreasen, et al.
Published: (2021-07-01)